Clinical trials: Aromatase Inhibitors
Fertility
Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women
A single center, open label randomized clinical trial designed to examine ovarian follicular dynamics following attempted atresia induction during the late follicular and early luteal phase of the menstrual cycle using an…
- Trial name
- NCT01046578
- Testing
- Letrozole
- Where
- Canada
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
Breast Cancer Females
Chronic Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. Despite the evidence that aromatase inhibitor therapy is associated with increased risk of cardiovascular events, potentially related to…
- Trial name
- STRIVE-Chronic (NCT06776458)
- Testing
- N/A - Usual Care
- Where
- Canada
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Breast Cancer Survivors
Adherence to Aromatase Inhibitors: The Role of Partners
This is a qualitative study which explores the role that partners play in breast cancer survivors adherence to aromatase inhibitors and management of their side effects.
- Trial name
- NCT02753985
- Testing
- Survey
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Menstruation Disorders
Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers
Aromatase inhibitors have been approved for use in postmenopausal women to treat and prevent breast cancer. They act by blocking the action of the enzyme, aromatase, that is necessary for the production of estradiol.
- Trial name
- NCT00467493
- Testing
- Anastrozole
- Where
- 2 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Meditrina Pharmaceuticals
Uterine Adenomyosis, Recurrent Implantation Failure
Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis
With this study the investigators want to test which is the best medical treatment for symptomatic adenomyosis affecting women undergoing IVF and with previous implantation failure, between Aromatase inhibitor plus GnRH analog…
- Conditions
- Uterine Adenomyosis, Recurrent Implantation Failure, Menstrual Pain
- Trial name
- NCT03421639
- Testing
- GnRH analog (11.25mg Leuprolide acetate), Aromatase inhibitor and GnRH analog, Aromatase and GnRH analog (11.25mg Leuprolide acetate)
- Where
- 3 sites in Albania, Bulgaria and 1 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Centre for Endocrinology and Reproductive Medicine, Italy
PCOS (Polycystic Ovary Syndrome), Infertility
Letrozole Extended vs Traditional Therapy for Ovulation Induction in Women With PCOS (PROLEx-PCOS)
This randomized clinical trial aims to compare the efficacy and safety of extended letrozole therapy (5 mg/day for 10 days) versus standard letrozole therapy (5 mg/day for 5 days) for ovulation induction in women with polycystic…
- Conditions
- PCOS (Polycystic Ovary Syndrome), Infertility, Anovulation
- Trial name
- PROLEx-PCOS (NCT07159880)
- Testing
- Traditional Letrozole Therapy, Extended Letrozole Therapy
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GABRIEL MONTEIRO PINHEIRO
Hormone Receptor-Positive Breast Cancer
Estradiol Levels According to Body Mass Index in Premenopausal Patients With Breast Cancer
his prospective observational study will evaluate whether body mass index (BMI) is associated with serum estradiol levels in premenopausal women with hormone receptor-positive breast cancer.
- Trial name
- SIMPEC-E2 (NCT07833501)
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- D'Or Institute for Research and Education
Breast Cancer
The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer
This study explores how aromatase inhibitor therapy affects risk factors for heart disease in postmenopausal women with breast cancer.
- Trial name
- Silhouette (NCT01080170)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Endometrial Neoplasm Malignant Stage I
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
To see if Gonadotropin-releasing hormone analogue (GnRHa) combined with aromatase inhibitors (AIs) will achieve better complete response rate than megestrol acetate or medroxyprogesterone acetate (MA/MPA) alone as…
- Trial name
- NCT05247268
- Testing
- Megestrol Acetate 160 MG Oral Tablet, Medroxyprogesterone Acetate 500 MG, Triprorelin Acetate
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Fudan University
Cognitive Side Effects of Cancer Therapy, Hypoestrogenism
ENDO-BRAIN: Effects of Endocrine Adjuvant Therapy with Aromatase Inhibitors on the Cognitive Function of Breast Cancer Patients
The principal aim of this prospective observational study is to investigate the cognitive function of breast cancer patients that use AI, comparing it with age-matched healthy controls, utilizing cognitive assessments and…
- Trial name
- ENDO-BRAIN (NCT06606535)
- Testing
- validated questionnaires, functional MRI, Optical Coherent Tomography Angiography
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ospedale Policlinico San Martino
Breast Cancer
The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women
The role of estrogens in the pathogenesis of breast cancer has been well documented. This has led to the development of "Anti-Estrogens" (selective estrogens receptor modulators and Aromatase Inhibitors), used for treatment and…
- Trial name
- NCT00566553
- Testing
- Grape Seed Extract
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer
Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI)
This study is a primary investigation to determine the usefulness and safety of a short course of a relatively high dose of letrozole (a medication used to decrease the female hormone estrogen which is produced locally inside the…
- Trial name
- RFCLET2 (NCT01129622)
- Testing
- letrozole
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Mount Sinai Hospital, Canada
Sexuality
Breast Cancer, Sexuality and Black Cohosh
The purpose of this study is to evaluate the Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen or aromatase inhibitor through questionnaires.
- Trial name
- Cimicifuga (NCT02467686)
- Testing
- WHOQOL questionnaire, FSFI questionnaire, kupperman scale
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Irmandade da Santa Casa de Misericordia de Sao Paulo
Breast Cancer Females
Short-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. While there is a clear linear relationship between the duration of aromatase inhibitor use and the cumulative incidence of…
- Trial name
- STRIVE (Acute) (NCT06781762)
- Testing
- N/A (Usual Care)
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Breast Cancer, Aromatase Inhibitors
Combined Training on Body Composition of Postmenopausal Women Undergoing Treatment for Breast Cancer
Breast cancer is a multifactorial disease affecting women, and one of the treatments for its healing and survival is hormone therapy.
- Conditions
- Breast Cancer, Aromatase Inhibitors, Postmenopausal
- Trial name
- NCT02804308
- Testing
- Combined Training
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial
This phase II trial tests the safety and effectiveness of a dietary supplement called resistant potato starch for reducing musculoskeletal symptoms in patients with stage 0-III breast cancer or who are at high risk for breast…
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- AIMSS-RPS (NCT07443943)
- Testing
- Starch, Potato
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Breast Cancer
Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors
Current guidelines recommend endocrine treatment with aromatase inhibitors (AIs) in post-menopausal women with hormone receptor-positive breast cancer.
- Trial name
- AIMS (NCT01074320)
- Testing
- Other
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Breast Cancer
IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of IH636 grape seed extract may prevent breast cancer.
- Trial name
- NCT00100893
- Testing
- IH636 grape seed proanthocyanidin extract
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Metastatic Breast Cancer
Study of ESR1 Mutations in Metastatic Breast Cancer
The purpose of the study is to determine the frequency ESR1 mutations by Digital PCR in patient with metastatic breast cancer.
- Trial name
- FMER (NCT02473120)
- Testing
- Determination of ESR1 mutations
- Where
- France
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Centre Henri Becquerel
Polymorphism, CYP19
Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea
Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor.
- Conditions
- Polymorphism, CYP19, Aromatase Inhibitor
- Trial name
- CYP19 (NCT01137136)
- Where
- South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center